প্রচ্ছদ

High-Risk Localized and Locally Advanced Prostate Cancer

Around 20%–30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of “high-risk” may need to be validated first. Although recent advances in radiotherapy for prostate c...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
বিন্যাস: Online
ভাষা:ইংরেজি
প্রকাশিত: MDPI - Multidisciplinary Digital Publishing Institute 2023
বিষয়গুলি:
imaging modality
&nbsp
oligometastasis
radical prostatectomy
lymph node dissection
brachytherapy
hormonal therapy
neoadjuvant/adjuvant therapy
quality of life
local invasion
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnology
অনলাইন ব্যবহার করুন:ONIX_20230808_9783036581682_54
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
সংক্ষিপ্ত:Around 20%–30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of “high-risk” may need to be validated first. Although recent advances in radiotherapy for prostate cancer have yielded excellent long-term results, even in high-risk localized disease, there are no studies directly comparing it with local treatment options, such as prostatectomy. To address current challenges in high-risk localized and locally advanced prostate cancer, 12 original and 3 review articles covering aspects from basic research to clinical trials are published in this Special Issue.

অনুরূপ উপাদানগুলি